ARS PHARMACEUTICALS, INC reports a Return on Equity (ROE) of -322.92%.

What is SPRY's dividend yield?

ARS PHARMACEUTICALS, INC offers a dividend yield of 0.00%.

What is SPRY's Quality Score?

Our AI rates SPRY's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy SPRY?

Our AI Timing Score for SPRY is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does SPRY belong to?

ARS PHARMACEUTICALS, INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

SPRY (NASDAQ) Stock Analysis | ARS PHARMACEUTICALS, INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

SPRY AI Analysis Summary

Our AI summary for SPRY: ARS PHARMACEUTICALS, INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -322.92%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

SPRY

ARS PHARMACEUTICALS, INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 81

USD 5.13

-0.50 (-8.88%) Day Change

Watchlist Portfolio Compare Chart

1.58

D/E

-322.9%

ROE

-68.8%

ROA

0.00%

Div Yield

ARS PHARMACEUTICALS, INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 5.13 Price -0.50 (-8.88%) Day Change	NEWS SCORE: 81

SPRY, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	81
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	5.13
PBV / Sector	9.12 / 5.20
Earning Per Share	-1.82

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	15.01 M GREAT
Average 1W Daily Value	15.06 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-200.00 / 98.71
NPM Average (%) / Sector	-36,849.27 / -1,721.76
NPM Change Average (%) / Sector	1,077.27 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-68.84 / 27.02
ROA Average (%) / Sector	-30.90 / -368.17
ROA Change Average (%) / Sector	-596.07 / 5,404.12
ROE (%) / Sector	-322.92 / 3.47
ROE Average (%) / Sector	-101.20 / 6.51
ROE Change Average (%) / Sector	-1,206.53 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:31
Symbol	SPRY
Name	ARS PHARMACEUTICALS, INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	99.30 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	559.08 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 11682 El Camino Real, San Diego, CA, United States, 92130

Phone: 858 771 9307

Website: https://ars-pharma.com

Employees: 154

Sector: Healthcare >> Biotechnology

Description: ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.